Scientists edited DNA in human embryos with unprecedented precision

A research team led by geneticist Dieter Egli at Columbia University in New York has developed a new and highly precise technique called 'base editing' to edit the DNA of human embryos. This innovative method aims to replace adenine (A), one of the four basic letters of the genetic alphabet, with guanine (G) by inserting a specially designed protein into the embryos. This protein works together with an RNA guide so that it can be accurately directed to the region where the targeted genetic change will occur. Thus, a much more controlled and specific genetic intervention is performed at the desired point. Researchers believe that this new technique could usher in a promising new era for the definitive treatment of genetic diseases.

To test this new editing method, scientists conducted studies on the PCSK9 gene, which is linked to heart disorders, and the HBG gene, which is connected to thalassemia, a blood disease that can cause anemia. Targeting these two specific genes demonstrates that the method could be used as a potential treatment against both hereditary heart diseases and blood disorders. The research reveals that the desired changes in the genetic sequences causing the problems were carried out with a high success rate through this technique. This is considered a significant step toward preventing serious diseases at the embryonic stage in the future. The study suggests that interventions on human DNA could enable the development of healthy individuals by focusing directly on the regions that cause disease.

The biggest claim of the developed 'base editing' technique is that it is much safer and more precise than the CRISPR technology, which is widely used and has become popular in genetic research today. Various scientific experiments conducted in recent years have shown that the CRISPR method can sometimes inadvertently alter genetic regions outside the targeted point, and can even lead to irreversible damage and fragmentation in chromosomes. Due to such undesired side effects, CRISPR is not yet fully accepted as a safely applicable method on human DNA. The new method presented by Egli's team minimizes this margin of error, ensuring that only the intended genetic letter is changed. Therefore, this technique stands out as an alternative that could open the door to safe clinical applications on human embryos.

The issue of genetic editing on human embryos has always been the subject of major ethical debates and intense legal processes in the scientific world. In 2018, the announcement by Chinese scientist He Jiankui that he had altered the genetic code of two human embryos using CRISPR and that these embryos were born as healthy babies deeply shocked the international community. Following this scandalous incident, Jiankui was sentenced to three years in prison by a court on charges of violating medical ethics rules. This event has painfully demonstrated how serious the consequences of interventions that permanently alter human genetics can be, and that they require strict oversight. In this context, the new and safer technique developed by the team at Columbia University aims to make the trajectory of scientific development in this field more controlled, even if it does not completely eliminate medical ethical concerns.

Although the scientific community finds these new findings extremely exciting, there are still serious obstacles that must be overcome before the 'base editing' method can enter routine clinical use. It is noted that there is no guarantee that these successful results obtained on embryos in a laboratory setting will work with similar perfection in a living human organism. Furthermore, it is not yet fully known what long-term and unpredictable effects such genetic changes made at the embryonic stage will have on the metabolisms of these babies as they grow, or on future generations. For this reason, researchers emphasize the need for comprehensive safety tests and ethical evaluations spanning many years before this technique can be integrated into practical medical applications. Still, this study has secured its place in the scientific world as one of the strongest signals that the vision of treating hereditary diseases at the embryonic stage could become a reality in the future.